Topical interleukin 1 receptor antagonist promotes corneal transplant survival

Transplantation

Volumn 63, Issue 10, 1997, Pages 1501-1507

  Dana, M Reza ^a   Yamada, Jun ^a   Streilein, J Wayne ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYALURONIC ACID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; GRAFT REJECTION; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; KERATITIS; LANGERHANS CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; CORNEA; CORNEAL TRANSPLANTATION; GRAFT SURVIVAL; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; KERATITIS; LANGERHANS CELLS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS;

EID: 0030926098     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199705270-00022     Document Type: Article

References (58)

1. The Collaborative Corneal Transplantation Studies Research Group. The collaborative corneal transplantation studies (CCTS): effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol 1992; 110: 1392.
2. Niederkorn JY. Immune privilege and immune regulation in the eye. Adv Immunol 1990; 48: 191.
3. Streilein JW. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye 1995; 9: 236.
4. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189.
5. Mader TH, Stulting RD. The high-risk penetrating keratoplasty. Ophthalmol Clin North Am 1991; 4: 411.
6. Coster DJ. Mechanisms of corneal graft failure: the erosion of corneal privilege. Eye 1989; 2: 251.
7. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Ophthalmology 1994; 101: 1536.
8. Williams KA, Roder D, Esterman A, Muehlberg SM, Coster DJ, on Behalf of All Contributing Surgeons. Factors predictive of corneal graft survival: report from the Australian Corneal Graft Registry. Ophthalmology 1992; 99: 403.
9. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection: their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99: 599.
10. Volker-Dieben HJ, D'Amaro J, Kok-Van Alphen CC. Hierarchy of prognostic factors for corneal allograft survival. Aust N Z J Ophthalmol 1987; 15: 11.
11. Wilson SE, Kaufman HE. Graft failure after penetrating keratoplasty. Surv Ophthalmol 1990; 34: 325.
12. Hill JC, Maske R, Watson P. Corticosteroids in corneal graft rejection: oral versus single pulse therapy. Ophthalmology 1991; 98: 329.
13. Raizman M. Corticosteroid therapy of eye disease: fifty years later. Arch Ophthalmol 1996; 114: 1000.
14. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991; 35: 369.
15. Barraquer J. Immunosuppressive agents in penetrating keratoplasty. Am J Ophthalmol 1985; 100: 61.
16. Frangie JP, Leibowitz HM. Steroids. Int Ophthalmol Clin 1993; 33: 9.
17. Niederkorn JY, Peeler JS, Mellon J. Phagocytosis of particulate antigens by corneal epithelial cells stimulates interleukin-1 secretion and migration of Langerhans cells into the central cornea. Reg Immunol 1989; 2: 83.
18. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993; 328: 106.
19. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234.
20. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 1992; 11: 581.
21. Buchwald S, Friemel H, Plantikow A, Hudemann B, Bast R, Templin R. Clinical value of interleukin 1- and interleukin 2-determinations in patients after kidney transplantation. Allerg Immunol 1990; 36: 137.
22. Takasu S, Sakagami K, Orita K. A new immunosuppressant, 15-deoxyspergualin, inhibits production of IL-1 from isolated hepatic sinusoidal lining cells in swine liver transplantation. Transplant Proc 1989; 21: 1081.
23. Tilg H, Vogel W, Aulitzky WE, et al. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990; 49: 1074.
24. BenEzra D, Hemo I, Maftzir G. In vivo angiogenic activity of interleukins. Arch Ophthalmol 1990; 108: 573.
25. Kijlstra A. The role of cytokines in ocular inflammation. Br J Ophthalmol 1994; 78: 885.
26. Girard MT, Matsubara M, Fini ME. Transforming growth factor-beta and interleukin-1 modulate metalloproteinase expression by corneal stromal cells. Invest Ophthalmol Vis Sci 1991; 32: 2441.
27. West-Mays JA, Strissel KJ, Sadow PM, Fini ME. Competence for collagenase gene expression by tissue fibroblasts requires activation of an interleukin 1 alpha autocrine loop. Proc Natl Acad Sci USA 1995; 92: 6768.
28. Shams NB, Reddy CV, Watanabe K, Elgebaly SA, Hanninen LA, Kenyon KR. Increased interleukin-1 activity in the injured vitamin A-deficient cornea. Cornea 1994; 13: 156.
29. Staats HF, Lausch RN. Cytokine expression in vivo during murine herpetic stromal keratitis: effect of protective antibody therapy. J Immunol 1993; 151: 277.
30. Niederkorn JY. Effect of cytokine-induced migration of Langerhans cells on corneal allograft survival. Eye 1995; 9: 215.
31. Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336.
32. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341.
33. Antin JH, Weinstein HJ, Guinan EC, et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 1994; 84: 1342.
34. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348: 550.
35. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996; 37: 2485.
36. Sano Y, Ksander BR, Streilein JW. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995; 36: 2176.
37. Sonoda Y, Streilein JW. Orthotopic corneal transplantation in mice-evidence that the immunogenetic rules of rejection do not apply. Transplantation 1992; 54: 694.
38. Gillette TE, Chandler JW, Greiner JV. Langerhans cells of the ocular surface. Ophthalmology 1982; 89: 700.
39. Williamson JSP, DiMarco S, Streilein JW. Immunobiology of Langerhans cells on the ocular surface: I. Langerhans cells within the central cornea interfere with induction of anterior chamber associated immune deviation. Invest Ophthalmol Vis Sci 1987; 28: 1527.
40. Dana MR, Schaumberg DA, Kowal VO, et al. Corneal neovascularization after penetrating keratoplasty. Cornea 1995; 14: 604.
41. McLeish W, Rubsamen P, Atherton SS, Streilein JW. Immunobiology of Langerhans cells on the ocular surface: II. Role of central corneal Langerhans cells in stromal keratitis following experimental HSV-1 infection in mice. Reg Immunol 1989; 2: 236.
42. Van der Veen G, Broersma L, Dijkstra CD, Van Rooijen N, Van Rij G, Van der Gaag R. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci 1994; 35: 3505.
43. Streilein JW, Bradley D, Sano Y, Sonoda Y. Immunosuppressive properties of tissues obtained from eyes with experimentally manipulated corneas. Invest Ophthalmol Vis Sci 1996; 37: 413.
44. Briscoe DM, DesRoches LE, Kiely JM, Lederer JA, Lichtman AH. Antigen-dependent activation of T helper cell subsets by endothelium. Transplantation 1995; 59: 1638.
45. Pober JS, Cotran RS. Immunologic interactions of T lymphocytes with vascular endothelium. Adv Immunol 1991; 50: 261.
46. Collin HB. Corneal lymphatics in alloxan vascularized rabbit eyes. Invest Ophthalmol 1966; 5: 1.
47. Pavilack MA, Einer VM, Einer SG, Todd RF III, Huber AR. Differential expression of human corneal and perilimbal ICAM-1 by inflammatory cytokines. Invest Ophthalmol Vis Sci 1992; 33: 564.
48. Gerritsen ME, Niedbala MJ, Szczepanski A, Carley WW. Cytokine activation of human macro- and microvessel-derived endothelial cells. Blood Cells 1993; 19: 325.
49. Heufler C, Koch F, Schuler G. Granulocyte/macrophage colony-stimulating factor and interleukin 1 mediate the maturation of murine epidermal Langerhans cells into potent immunostimulatory dendritic cells. J Exp Med 1988; 167: 700.
50. Kennedy MC, Rosenbaum JT, Brown J, et al. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. J Cl Invest 1995; 95: 82.
51. Burstein NL. Basic science of ocular pharmacology. In: Bartlett JD, Jaanus SD, eds. Clinical ocular pharmacology, 2nd ed. Boston: Butterworth, 1989: 3.
52. Saettone MF, Giannaccini B, Savigni P, Wirth A. The effect of different ophthalmic vehicles on the activity of tropicamide in man. J Pharm Pharmacol 1980; 32: 519.
53. Snibson GR, Greaves JL, Soper ND, Tiffany JM, Wilson CG, Bron AJ. Ocular surface residence times of artificial tear solutions. Cornea 1992; 11: 288.
54. Sand BB, Marner K, Norn MS. Sodium hyaluronate in the treatment of keratoconjunctivitis sicca: a double masked clinical trial. Acta Ophthalmol 1989; 67: 181.
55. Shams NB, Sigel MM, Davis RM. Interferon-gamma, Staphylococcus aureus, and lipopolysaccharide/silica enhance interleukin-1 beta production by human corneal cells. Reg Immunol 1989; 2: 136.
56. Kondo S, Pastore S, Fujisawa H, et al. Interleukin-1 receptor antagonist suppresses contact hypersensitivity. J Invest Dermatol 1995; 105: 334.
57. Rosenbaum JT, Boney RS. Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch Ophthalmol 1992; 110: 547.
58. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627.